Mesna 200

Mesna:for prevention of urothelial toxicity in patients treated with antineoplastics ifosfamide or cyclophosphamide. In the kidney, dimesna, This has thiol groups that react with the metabolites of ifosfamide and cyclophosphamide, including acrolein, which are considered to be responsible for the toxic effects on the bladder.
Adverse effects: headache, fatigue, limb pains,depression,irritability,hypotension ,tachycardia, and skin rash
Dosage: If ifosfamide or cyclophosphamide is given as an intravenous bolus, the intravenous Dose ofmesna is 20% of the Dose of the antineoplastic on a weight for weight basis given on 3 occasions over 15 to 30 minutes at intervals of 4 hours beginning at the same time as the antineoplastic injectio.